Otonomy Initiates Patient Enrollment in Single Phase 3 Clinical Trial of OTIPRIO™ in Patients with Acute Otitis Externa
09 juin 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, June 09, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO™
20 mai 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 20, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces OTIPRIO™ Data Presentation and Symposium at Combined Otolaryngology Spring Meetings
16 mai 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 16, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Reports First Quarter 2016 Financial Results and Provides Corporate Update
09 mai 2016 16h15 HE
|
Otonomy, Inc.
SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Present at the Bank of America Merrill Lynch Healthcare Conference
05 mai 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 05, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Announces Phase 3 Clinical Trial Plan for OTIPRIO™ in Otitis Externa Patients Based on Successful End-of-Phase 2 Review by FDA
18 avr. 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, April 18, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Ménière’s Disease
23 mars 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, March 23, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
07 mars 2016 16h14 HE
|
Otonomy, Inc.
SAN DIEGO, March 07, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Initiates Phase 2 Clinical Trial of OTIPRIO™ in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
03 mars 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, March 03, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Announces Commercial Availability of OTIPRIO™
02 mars 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, March 02, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...